What does Upstream Bio, Inc. do?
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease…
What is Upstream Bio, Inc.'s P/E and P/B ratio?
Upstream Bio, Inc. has a P/E ratio of -1.0 and a P/B ratio of 0.60.
What is Upstream Bio, Inc.'s debt-to-equity ratio?
Upstream Bio, Inc. has a debt-to-equity ratio of 0.00.
How much does Upstream Bio, Inc. owe compared with what it owns?
Upstream Bio, Inc. owes $0.04 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Upstream Bio, Inc.'s Positivity rank?
Upstream Bio, Inc. is ranked #775 of 6,775 companies globally and #119 of 4,000 in United States on PositoAI, with a Positivity Score of 23,841.
Does Upstream Bio, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Upstream Bio, Inc..
Where can I read the latest news about Upstream Bio, Inc.?
Recent headlines about Upstream Bio, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Upstream Bio, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Upstream Bio, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.